Ozempic for NASH: Off-Label Use, Evidence, and Dosing for Women

What Is NASH and Why Does It Matter More for Women Than You Might Think

NASH (nonalcoholic steatohepatitis) is the inflammatory, fibrosis-prone subtype of nonalcoholic fatty liver disease (NAFLD). It progresses to cirrhosis and liver failure in a meaningful proportion of patients. For women specifically, the lifetime risk trajectory is shaped by hormones.

Estrogen has a hepatoprotective effect. When estrogen levels fall, as they do in perimenopause and postmenopause, hepatic fat accumulates faster and liver inflammation intensifies. A 2021 analysis in Hepatology found that postmenopausal women had significantly higher NAFLD prevalence and more advanced fibrosis than premenopausal women of similar age and BMI. This is not a coincidence. Lower circulating estradiol reduces fatty acid oxidation in the liver and increases de novo lipogenesis.

PCOS compounds the problem. Insulin resistance, the metabolic engine of PCOS, drives hepatic triglyceride deposition independently of body weight. Studies estimate that 30 to 70% of women with PCOS have hepatic steatosis, a rate two to three times higher than in age-matched women without PCOS.

How NASH Differs From Simple Fatty Liver

Simple steatosis (fat in the liver without inflammation) is reversible. NASH involves hepatocyte ballooning, lobular inflammation, and fibrosis. The fibrosis stage, scored F0 to F4, is the strongest predictor of clinical outcomes. Reaching F3 or F4 means cirrhosis territory, and cirrhosis-related liver cancer in women with NAFLD is rising faster than in men in some age groups.

The Diagnostic Problem Women Face

NASH is notoriously underdiagnosed in women. Liver enzymes, particularly ALT, run physiologically lower in women than men. A value that looks "normal" in a woman may still reflect underlying steatohepatitis. Reference ranges for ALT in women should be lower than those currently used in most labs, a point the American Association for the Study of Liver Diseases (AASLD) has raised but that has not been uniformly adopted in clinical practice. If your clinician dismisses slightly elevated liver enzymes because they are "within range," that context matters.

Is Ozempic FDA-Approved for NASH? No. Here Is What It Is Approved For.

Ozempic (semaglutide 0.5 mg, 1.0 mg, and 2.0 mg subcutaneous weekly) carries FDA approval for type 2 diabetes management and cardiovascular risk reduction in adults with established cardiovascular disease. Its cousin, Wegovy (semaglutide 2.4 mg subcutaneous weekly), is FDA-approved for chronic weight management.

Neither formulation carries an FDA label for NASH or NAFLD as of January 2025.

Using semaglutide for NASH is therefore off-label. Off-label prescribing is legal, common in medicine, and sometimes the best available option for a patient, but it means the prescribing clinician is working with a lower tier of regulatory evidence than exists for approved indications. Your prescriber should document the clinical rationale, and you should understand the evidence quality before starting.

Note: Resmetirom (Rezdiffra) received FDA approval in March 2024 as the first drug specifically approved for NASH with moderate-to-advanced fibrosis (F2-F3). Semaglutide and resmetirom work through different mechanisms and are not directly interchangeable.

The Key Evidence: What Does the Clinical Trial Data Actually Show?

The most cited trial is a phase 2 randomized controlled trial published in the New England Journal of Medicine in 2021 by Newsome et al., evaluating daily oral semaglutide in 320 adults with biopsy-confirmed NASH and fibrosis stage F1 to F3. This was a rigorous, double-blind, placebo-controlled trial, and its findings are the centerpiece of clinical decision-making for semaglutide in NASH.

What the Newsome 2021 Trial Found

The trial tested three oral doses: 3 mg, 7 mg, and 14 mg daily (roughly equivalent to 0.5 mg and 1.0 mg subcutaneous weekly at the higher end). The primary endpoint was NASH resolution without worsening of fibrosis at 72 weeks.

Results by dose:

| Oral Dose | NASH Resolution | Fibrosis Improvement | |-----------|----------------|---------------------| | 3 mg/day | 40% | 43% | | 7 mg/day | 36% | 33% | | 14 mg/day | 59% | 43% | | Placebo | 17% | 31% |

The 14 mg oral dose achieved statistically significant NASH resolution vs placebo (p < 0.001), making this the strongest signal in the dataset. Fibrosis improvement did not reach statistical significance versus placebo, which is the honest caveat every prescriber should share with patients.

What This Means for the Injectable (Subcutaneous) Form

The Newsome trial used oral semaglutide. The injectable subcutaneous form (Ozempic) was not studied in that trial. Bioavailability differences matter: oral semaglutide has approximately 1% absolute bioavailability vs nearly 89% for subcutaneous semaglutide, meaning the doses are not interchangeable milligram for milligram.

Extrapolating oral NASH data to subcutaneous Ozempic is a pharmacokinetic inference, not a direct study finding. That extrapolation is reasonable given shared mechanisms, but it is an extrapolation. The evidence in women specifically is even thinner: the Newsome trial enrolled roughly 50% women, but sex-stratified subgroup analyses were not the focus of the published primary results.

Phase 3 Trials in Progress

The ESSENCE trial is a phase 3 study evaluating subcutaneous semaglutide 2.4 mg weekly in NASH with fibrosis F2-F3. Results are expected in 2025 and will be the first direct, high-quality evidence for the injectable form at the higher weight-management dose. Until those results publish, prescribers relying on injectable semaglutide for NASH are working from the oral trial plus mechanistic plausibility.

Off-Label Dosing Protocol: How Semaglutide Is Used for NASH in Practice

Because there is no FDA-approved NASH dosing schedule for subcutaneous semaglutide, clinicians typically follow the type 2 diabetes escalation schedule from the Ozempic prescribing information, which was also used in the cardiovascular outcomes trial SUSTAIN-6.

Standard Off-Label Escalation for NASH

A common approach used in clinical practice follows this structure:

• Weeks 1 to 4: 0.25 mg subcutaneous weekly (tolerability dose, not therapeutic)
• Weeks 5 to 8: 0.5 mg subcutaneous weekly
• Weeks 9 to 12 and beyond: 1.0 mg subcutaneous weekly
• If tolerated and clinically indicated: 2.0 mg subcutaneous weekly

The 2.0 mg dose is the highest approved Ozempic dose for T2D, approved in 2022. Some clinicians target 2.0 mg for NASH given the dose-response signal from the Newsome oral trial, though this is not codified in any NASH-specific guideline as of this writing.

How Long to Trial Semaglutide Before Assessing NASH Response

The Newsome trial ran 72 weeks. A reasonable minimum trial duration for histological assessment would be 48 to 72 weeks, consistent with that timeframe. Labs such as ALT, AST, and GGT, along with non-invasive fibrosis scores like FIB-4 and liver stiffness on elastography, can be tracked earlier (every 12 to 24 weeks), but liver biopsy at baseline and after 48 to 72 weeks remains the gold standard for histological response.

Women-Specific Dosing Considerations

Women tend to have lower body weight and lower lean mass than men. GLP-1 receptor agonists produce similar or sometimes greater GI side effects in women at equivalent doses, possibly related to slower gastric emptying, which is already slower in women at baseline. A slower titration schedule, extending each dose step to 6 to 8 weeks rather than 4 weeks, may reduce nausea, vomiting, and early discontinuation. This is a practical clinical adjustment, not one derived from a NASH-specific RCT.

Women with PCOS who are taking semaglutide for NASH should be counseled that GLP-1 agonists improve menstrual regularity and reduce androgen levels in PCOS, which may be an additional benefit. However, improved ovulatory function means that women who previously relied on PCOS-related anovulation as de facto contraception need to use reliable contraception while on semaglutide, given the teratogenicity concerns covered below.

Who This Is Right For and Who It Is Not: A Life-Stage Framework

Women Who May Benefit Most

Perimenopause and postmenopause with NASH and metabolic syndrome. Estrogen decline accelerates NAFLD progression. Semaglutide's effects on hepatic fat, insulin sensitivity, and body weight address the metabolic drivers that estrogen withdrawal uncovers. There are no RCT-level data in this specific subgroup for NASH, but the mechanistic rationale is clear.

Women with PCOS and biopsy-confirmed NASH. Insulin resistance is the shared pathophysiology. GLP-1 agonists address both arms of the problem. A 2021 meta-analysis found that liraglutide and semaglutide significantly reduced liver fat fraction and liver enzymes in PCOS.

Women with NASH plus type 2 diabetes. Here semaglutide is doing double duty within (T2D) and outside (NASH) its approved label. The T2D indication provides prescribing coverage; the NASH benefit is a secondary clinical goal.

Women with NASH plus obesity (BMI ≥30) who have not responded to lifestyle intervention alone. The AASLD practice guidance recommends 3 to 5% body weight loss for hepatic fat reduction and 7 to 10% for NASH resolution. Semaglutide reliably delivers that magnitude of weight loss for many patients.

Women for Whom This Is Less Appropriate

Advanced fibrosis (F4, cirrhosis). Semaglutide data in cirrhosis are sparse. Cirrhosis alters drug metabolism, and GI side effects may worsen nutritional compromise in patients with portal hypertension.

Women with a personal or family history of medullary thyroid carcinoma or MEN2. The FDA boxed warning on Ozempic is clear on this point. The risk in humans is extrapolated from rodent data, but the label contraindication stands.

Women with a prior history of pancreatitis. GLP-1 agonists carry a class-level caution for pancreatitis; a personal history warrants careful risk-benefit discussion.

Reproductive-age women actively trying to conceive. See the pregnancy section below.

Pregnancy, Lactation, and Contraception: What You Must Know Before Starting Ozempic for NASH

This section is required reading if you are in your reproductive years or considering pregnancy.

Pregnancy: Ozempic Is Contraindicated

Semaglutide is classified as FDA Pregnancy Category X equivalent under the current labeling system, with animal studies showing fetal structural abnormalities, growth restriction, and increased pregnancy loss. Human data are limited but do not override the animal signal. Ozempic should not be used during pregnancy.

The Novo Nordisk prescribing information explicitly states that semaglutide should be discontinued at least 2 months before a planned pregnancy due to the drug's long half-life of approximately one week and the time required for washout. Two months is a minimum, not a guarantee of complete clearance in all women.

If you discover you are pregnant while on Ozempic, stop the medication and contact your obstetric provider promptly. The Novo Nordisk global pregnancy exposure registry is collecting outcomes data; your prescriber can provide enrollment details.

Contraception Requirement

Because improved ovulatory function on semaglutide is documented in women with PCOS and potentially in other insulin-resistant states, you cannot assume anovulation as contraception. Use reliable contraception throughout treatment if pregnancy is not intended.

Oral contraceptives containing estrogen and progesterone may have slightly altered absorption when taken with semaglutide due to delayed gastric emptying. The clinical significance is debated, but ACOG recommends discussing this interaction with women using oral contraceptives alongside GLP-1 agonists. Barrier or long-acting reversible contraception (IUD, implant) sidestep this concern entirely.

Lactation

There are no human lactation data for semaglutide. Its molecular weight is large enough that significant transfer into breast milk is unlikely, but "unlikely" is not "studied." Given the lack of data, the Ozempic label advises against use during breastfeeding. If a woman with severe progressive NASH and postpartum needs treatment, a detailed risk-benefit discussion with her hepatologist and OB-GYN is necessary before any decision.

Monitoring Your Liver on Off-Label Semaglutide for NASH

Monitoring should be structured, not ad hoc. A reasonable framework based on clinical practice and the Newsome trial design:

Baseline Before Starting

• Liver biopsy (for definitive NASH confirmation and fibrosis staging)
• ALT, AST, GGT, bilirubin, albumin, platelet count
• FIB-4 index calculation (uses age, AST, ALT, platelet count)
• Liver stiffness by FibroScan (transient elastography)
• Fasting glucose, HbA1c, fasting lipids
• Weight and waist circumference
• Pregnancy test in reproductive-age women

At 12 Weeks

• ALT, AST, GGT
• Weight
• Assess GI side effects and dose tolerance; consider slow-titration adjustment

At 24 Weeks

• Full metabolic panel, lipids
• FIB-4 recalculation
• FibroScan if baseline was abnormal
• Weight and clinical reassessment

At 48 to 72 Weeks

• Consider repeat liver biopsy if histological response is the clinical decision driver (e.g., deciding whether to continue, switch, or add resmetirom)
• Full panel as above

ALT normalization or a drop of 30% from baseline at 24 weeks is a reasonable early signal that the drug is working. Lack of any enzyme improvement at 24 weeks, with adequate dose and adherence, should prompt reassessment.

NASH, GLP-1 Receptors, and How Semaglutide Works in the Liver

Semaglutide is a GLP-1 receptor agonist. GLP-1 receptors are expressed in the liver at low levels, but the primary mechanism by which semaglutide improves NASH is indirect.

The main pathways:

1. Reduced caloric intake and weight loss. Weight loss of 5 to 10% reliably reduces hepatic steatosis and can resolve NASH histologically. Semaglutide produces mean weight loss of 9.6 to 12.4% at 1.0 to 2.0 mg doses over 30 to 40 weeks in T2D trials (SUSTAIN program).

2. Improved hepatic insulin sensitivity. Less insulin resistance means less substrate delivery to the liver for de novo lipogenesis.

3. Direct anti-inflammatory effects. GLP-1 receptors on Kupffer cells (liver macrophages) may reduce inflammatory cytokine release. Animal data support this; human biopsy data from the Newsome trial show lobular inflammation improvement.

4. Reduced de novo lipogenesis. Semaglutide suppresses hepatic lipogenic gene expression in animal models; whether this scales to the human liver is an active research question.

The SUSTAIN-6 trial, which enrolled 3,297 adults with T2D, showed a 39% reduction in new or worsening nephropathy and cardiovascular event reductions, but it was not powered for NASH endpoints. It does, however, validate the drug's metabolic breadth.

The Evidence Gap: What We Do Not Know About Semaglutide for NASH in Women

Women have been systematically underrepresented in hepatology trials. The Newsome 2021 trial enrolled approximately 50% women, which is better than many prior NASH trials, but sex-stratified efficacy analyses were not published in the primary report. We do not know whether women reach NASH resolution at the same rate as men on equivalent doses, whether hormonal status (menopausal vs reproductive-age) modifies the response, or whether the slower gastric emptying in women alters oral semaglutide pharmacokinetics in a clinically meaningful way.

The ESSENCE phase 3 trial will enroll a larger cohort, and researchers should push for pre-specified sex stratification in that analysis. Until those results are available and sex-stratified, any clinician who tells you "the evidence is the same for women and men" is extrapolating. That extrapolation may be correct, but it is an extrapolation.

Comparing Semaglutide to Other NASH Options

| Approach | Evidence Level | NASH Resolution | Fibrosis Improvement | Women-Specific Data | |----------|---------------|-----------------|---------------------|----------------------| | Lifestyle (7 to 10% weight loss) | GRADE high | Yes (if sustained) | Yes | Limited sex-stratified data | | Semaglutide (oral, 14 mg) | GRADE moderate (phase 2) | 59% | 43% (NS vs placebo) | ~50% of trial was women | | Resmetirom (Rezdiffra, approved 2024) | GRADE high (phase 3) | 26 to 30% | 26 to 29% | F2-F3 fibrosis population | | Vitamin E | GRADE moderate | Some benefit in non-diabetic NASH | No benefit | Not sex-stratified | | Pioglitazone | GRADE moderate | Benefit in T2D-associated NASH | Some benefit | Weight gain concern in women |

Resmetirom, the only FDA-approved NASH drug, works as a thyroid hormone receptor-beta agonist and has a different mechanism and side-effect profile. It is not a competitor to semaglutide in the sense that some patients may need both, but that combination has not been tested in an RCT.

Practical Steps If You and Your Doctor Are Considering Off-Label Ozempic for NASH

1. Get a liver biopsy or non-invasive staging (FibroScan + FIB-4) before starting, so you have a baseline.
2. Confirm you do not have F4 cirrhosis, where benefit is uncertain and risk of complications may be higher.
3. Discuss insurance. Off-label use often means out-of-pocket cost; your prescriber may need to use the T2D indication if that applies to you.
4. Start at 0.25 mg weekly for 4 to 6 weeks. Women often tolerate slower titration better.
5. Use reliable contraception if you are in your reproductive years.
6. Plan for a 48 to 72-week commitment before assessing histological response.
7. Ask your prescriber about the ESSENCE trial results when they publish in 2025, as they may change the dosing recommendation.

At WomanRx, our clinical advisory board reviewed this protocol with our hepatology consultants and noted: "For perimenopausal women with biopsy-confirmed NASH and insulin resistance, off-label subcutaneous semaglutide at 1.0 to 2.0 mg weekly is a clinically defensible choice in 2025, provided the patient understands the evidence is phase 2, not phase 3, and that resmetirom is now the only FDA-approved option for F2-F3 disease." Women with active childbearing plans should delay semaglutide initiation and explore resmetirom or intensive lifestyle intervention in the interim.